Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab
Clinical and Experimental Medicine · 06.08.2024 · 24 (1)
DOI: 10.1007/s10238-024-01427-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Medicine, online erschienen am 06.08.2024. Verfasst von Carlo Genova und 27 weiteren Autor:innen. Beteiligte Einrichtung: UOC Clinica Di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, 16132, Genoa, Italy. Hauptthemen laut MEDLINE: MicroRNAs, Carcinoma, Non-Small-Cell Lung, Nivolumab, Lung Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute, Bristol-Myers Squibb, Compagnia di San Paolo.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have revolutionized the management of advanced non-small cell lung cancer (NSCLC), although patient survival is still unsatisfactory. Accurate predictive markers capable of personalizing the treatment of patients with NSCLC are still lacking. Circulating extracellular vesicles involved in cell-to-cell communications through miRNAs (EV-miRs) transfer are promising markers. Plasma from 245 patients with advanced NSCLC who received nivolumab as second-line therapy was collected and analyzed. EV-miRnome was profiled on 174/245 patients by microarray platform, and selected EV-miRs were validated by qPCR. A prognostic model combining EV-miR and clinical variables was built using stepwise Cox regression analysis and tested on an independent patient cohort (71/245). EV- PD-L1 gene copy number was assessed by digital PCR. For 54 patients with disease control, EV-miR changes at best response versus baseline were investigated by microarray and validated by qPCR. EV-miRNome profiling at baseline identified two EV-miRs (miR-181a-5p and miR-574-5p) that, combined with performance status, are capable of discriminating patients unlikely from those that are likely to benefit from immunotherapy (median overall survival of 4 months or higher than 9 months, respectively). EV-PD-L1 digital evaluation reported higher baseline copy number in patients at increased risk of mortality, without improving the prognostic score. Best response EV-miRNome profiling selected six deregulated EV-miRs (miR19a-3p, miR-20a-5p, miR-142-3p, miR-1260a, miR-1260b, and miR-5100) in responding patients. Their longitudinal monitoring highlighted a significant downmodulation already in the first treatment cycles, which lasted more than 6 months. Our results demonstrate that EV-miRs are promising prognostic markers for NSCLC patients treated with nivolumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UOC Clinica Di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, 16132, Genoa, Italy.
- Dipartimento Di Medicina Interna E Specialità Mediche (DiMI), Università Degli Studi Di Genova, Viale Benedetto XV, 6, 16132, Genoa, Italy.
- UOS Tumori Polmonari, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, 16132, Genoa, Italy.
- Laboratory of Cancer Genomics, Fondazione Edo Ed Elvo Tempia, Via Malta, 3, 13900, Biella, Italy. giovanna.chiorino@fondazionetempia.org.
- Laboratory of Cancer Genomics, Fondazione Edo Ed Elvo Tempia, Via Malta, 3, 13900, Biella, Italy.
- UOC Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, 16132, Genoa, Italy.
Förderung
- Ministero della Salute
- Bristol-Myers Squibb
- Compagnia di San Paolo
Zitieren
APA
Genova, C., Marconi, S., Chiorino, G., Guana, F., Ostano, P., Santamaria, S., Rossi, G., Vanni, I., Longo, L., Tagliamento, M., Zullo, L., Dal Bello, M. G., Dellepiane, C., Alama, A., Rijavec, E., Ludovini, V., Barletta, G., Passiglia, F., Metro, G., …, & Coco, S. (2024). Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab. Clinical and Experimental Medicine, 24(1). https://doi.org/10.1007/s10238-024-01427-8
Vancouver
Genova C, Marconi S, Chiorino G, Guana F, Ostano P, Santamaria S, et al. Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab. Clinical and Experimental Medicine. 2024;24(1). doi:10.1007/s10238-024-01427-8
BibTeX
@article{Genova2024,
author = {Genova, Carlo and Marconi, Silvia and Chiorino, Giovanna and Guana, Francesca and Ostano, Paola and Santamaria, Sara and Rossi, Giovanni and Vanni, Irene and Longo, Luca and Tagliamento, Marco and Zullo, Lodovica and Dal Bello, Maria Giovanna and Dellepiane, Chiara and Alama, Angela and Rijavec, Erika and Ludovini, Vienna and Barletta, Giulia and Passiglia, Francesco and Metro, Giulio and Baglivo, Sara and Chiari, Rita and Rivoltini, Licia and Biello, Federica and Baraibar, Iosune and Gil-Bazo, Ignacio and Novello, Silvia and Grossi, Francesco and Coco, Simona},
title = {Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab},
journal = {Clinical and Experimental Medicine},
year = {2024},
volume = {24},
number = {1},
doi = {10.1007/s10238-024-01427-8}
}
EUVIMED